Cancer vaccine market to hit $7B by 2015

Spurred by the recent approval of Dendreon's prostate cancer vaccine Provenge, a new report predicts that the cancer vaccine market will swell to a $7 billion industry by 2015. There are six types of vaccines in development, according to the report: antigen/adjuvant vaccines, DNA vaccines, vector-based vaccines, tumor cell vaccines, dendritic cell vaccines and anti-idiotype vaccines. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.